Vazyme(SH:688105) Xin Lang Cai Jing·2025-10-13 02:30Company Overview - NuoVant Biotechnology Co., Ltd. is located in Nanjing, Jiangsu Province, and was established on March 16, 2012. The company went public on November 15, 2021. It focuses on the research and development of functional proteins and high molecular organic materials, including enzymes, antigens, and antibodies [1] - The main business revenue composition includes: biological reagents 81.86%, diagnostic reagents 9.99%, consumables 3.15%, equipment 2.96%, technical services 1.85%, and others 0.18% [1] Financial Performance - As of June 30, the number of shareholders increased by 2.37% to 8,596, while the average circulating shares per person decreased by 2.31% to 46,269 shares [2] - For the first half of 2025, the company reported revenue of 606 million yuan, a year-on-year decrease of 6.63%, and a net profit attributable to shareholders of 3.1294 million yuan, down 80.63% year-on-year [2] - Since its A-share listing, the company has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3] Stock Performance - On October 13, the stock price of NuoVant fell by 2.06% to 22.30 yuan per share, with a trading volume of 19.9837 million yuan and a turnover rate of 0.22%. The total market capitalization is 8.869 billion yuan [1] - Year-to-date, the stock price has increased by 1.27%, but it has decreased by 2.53% over the last five trading days, 3.84% over the last 20 days, and 4.82% over the last 60 days [1] - The net outflow of main funds was 413,300 yuan, with large single purchases amounting to 986,600 yuan (4.94% of total) and sales of 1.3999 million yuan (7.00% of total) [1] Industry Position - NuoVant is classified under the pharmaceutical and biotechnology sector, specifically in the subcategory of biological products. It is involved in concepts such as gene sequencing, in vitro diagnostics, antigen testing, synthetic biology, and medical devices [1]